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OBJECTIVE— We investigated the effects of normal variations in maternal glycemia on birth
size and other birth outcomes.
RESEARCHDESIGNANDMETHODS— Women in two unselected birth cohorts, one
retrospective (n 3,158) and one prospective (n 668), underwent an oral glucose challenge
at 28 weeks of gestation. In the retrospective study, glycemia was linked to routine birth records.
In the prospective study, offspring adiposity was assessed by skinfold thickness from birth to age
24 months.
RESULTS— In the retrospective study, within the nondiabetic range (2.1–7.8 mmol/l), each
1 mmol/l rise in the mother’s 60-min glucose level was associated with a (mean SEM) 2.1 
0.8% (P  0.006) rise in absolute risk of assisted vaginal delivery, a 3.4  0.8% (P  0.0001)
rise in emergency cesarean delivery, a 3.1 0.7% (P 0.0001) rise in elective cesarean delivery,
and a 46  8 g (P  0.0001) increase in offspring birth weight. In the prospective study, fetal
macrosomia (birth weight 90th centile) was independently related to the mother’s fasting
glucose (odds ratio 2.61 per1 mmol/l [95% CI 1.15–5.93]) and prepregnancy BMI (1.10 per
1 kg/m2 [1.04–1.18]). The mother’s higher fasting glycemia (P  0.004), lower insulin
sensitivity (P  0.01), and lower insulin secretion (P  0.02) were independently related to
greater offspring adiposity at birth. During postnatal follow-up, the correlation between the
mother’s glycemia and offspring adiposity disappeared by 3 months, whereas prepregnancy BMI
was associated with offspring adiposity that was only apparent at 12 and 24 months (both P 
0.05).
CONCLUSIONS— Prepregnancy BMI, pregnancy glycemia, insulin sensitivity, and insulin
secretion all contribute to offspring adiposity and macrosomia and may be separate targets for
intervention to optimize birth outcomes and later offspring health.
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The international multicenter Hyper-glycemia and Adverse PregnancyOutcomes (HAPO) Study recently
reported that maternal fasting and stimu-
lated glucose levels showed linear effects
on risks for macrosomia, cesarian deliv-
ery, and neonatal hypoglycemia at birth
(1). These findings question the optimal
indicators used to manage maternal glu-
cose levels during pregnancy.
The elevation in maternal glycemia
during pregnancy is consequent to a rise
in maternal insulin resistance, which in
turn is attributed to hormonal changes,
such as placental growth hormone (2), or
to a maternal inflammatory response to
placental cells (3). Higher maternal glu-
cose levels facilitate glucose transport
across the placenta, which in turn pro-
motes fetal insulin secretion and fetal
growth (4). In addition to higher glucose
levels, maternal insulin resistance also el-
evates circulating amino acids and fatty
acids, and these nutrients could also stim-
ulate fetal insulin secretion and fetal
growth. Therefore, maternal BMI, insulin
sensitivity, and insulin secretion could all
contribute to offspring birth size and birth
outcomes.
We investigated the relationships be-
tween maternal insulin, glucose, and BMI
during pregnancy and offspring birth size
and adiposity in a prospective study with
follow-up of offspring to age 24 months.
In a separate large retrospective study, we
explored the nature of the relationship be-
tween maternal glycemia on birth weight
and mode of delivery.
RESEARCH DESIGN AND
METHODS— The retrospective co-
hort (the Cambridge Wellbeing Study)
comprised mothers identified from rou-
tine clinical data in an electronic database
of all deliveries at the Rosie Maternity
Hospital, Cambridge, U.K., between
1999 and 2000. The data were merged to
a biochemistry database of maternal ve-
nous blood glucose levels 60 min after a
50-g oral glucose load at 27–29 weeks of
gestation as a routine screening test for
gestational diabetes mellitus. Women
with 60-min glucose levels 7.8 mmol/l
were excluded from this study, as these
women would have been considered at
high risk of gestational diabetes mellitus
(5). We identified data for 3,158 Cauca-
sian women with normal glucose toler-
ance, who denied smoking or taking any
medication at the time of glucose testing
and who had a subsequent full-term
(37 weeks of gestation) singleton deliv-
ery. Birth weight was measured at deliv-
ery by the midwife.
The prospective cohort (the Cam-
bridge Baby Growth Study) was recruited
from mothers attending ultrasound clin-
ics during early pregnancy at the Rosie
Maternity Hospital between 2001 and
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2006. At 28 weeks of gestation, a 75-g
oral glucose load (oral glucose tolerance
test [OGTT]) was given. Venous blood
glucose and insulin levels were measured
at fasting and at 60 min, and capillary
blood glucose was measured at 30, 90,
and 120 min. Of a total of 708 women
who underwent an OGTT, we excluded
34 (4.8%) who had known diabetes, a
further 4 women who had a 120-min cap-
illary glucose level 8.6 mmol/l, and 2
women who had fasting venous glucose
6.1 mmol/l. Complete data on glucose
and insulin levels and offspring birth
weight were available for 668 nondiabetic
pregnant women with normal fasting glu-
cose and glucose tolerance. Birth weight
was measured by the midwife. Offspring
skinfold thicknesses (biceps, triceps, sub-
scapular, and suprailiac) were measured
at birth (7 days old). Measurements
were performed in duplicate by trained
research nurses using a Harpenden Skin-
fold Caliper (Holtain, Crosswell, Cry-
mych, Pembrokeshire, U.K.).
Ethical approval
Both studies were approved by the local
ethics committee, Addenbrooke’s Hospi-
tal, Cambridge, U.K. For the retrospective
Cambridge Wellbeing Study, we only an-
alyzed routinely collected and anony-
mized data, and therefore consent was not
required. For the prospective Cambridge
Baby Growth Study, written informed
consent was obtained from all mothers by
a research nurse.
Assays
In both cohorts, mother’s whole blood glu-
cose levels were taken from routine mea-
surements in the Clinical Biochemistry
Department, Addenbrooke’s Hospital,
U.K., using a standard glucose oxidase–
based assay. In the Cambridge Baby Growth
Study, fasting and stimulated insulin levels
were measured in the Department of Pedi-
atrics. Insulin was measured by enzyme-
linked immunosorbent assay using a
commercial kit (DSL, London, U.K.). Sen-
sitivity was 0.26 mU/l. Intra-assay coeffi-
cients of variation (CVs) were 4.4 and 5.1%
at 10.3 and 35.8 mU/l, and equivalent inter-
assay CVs were 8.7 and 2.9%; this assay has
no cross-reactivity with proinsulin at levels
up to 1,000 pmol/l.
Calculations
Insulin sensitivity was estimated using ho-
meostasis model assessment (HOMA) (6).
To estimate insulin secretion independent
of insulin sensitivity, we calculated the dis-
position index as the insulinogenic index
[(insulin 60 insulin 0)/(glucose 60 glu-
cose 0)] (7) divided by the insulin resistance
index (8). Offspring adiposity at ages 0, 3,
12, and 24 months was estimated as the
average of the standardized scores for the
four skinfold thickness measurements ad-
justed for age and sex.
Statistics
For the retrospective Cambridge Wellbe-
ing Study, glucose levels were categorized
into five groups (4, 4.1–5.0, 5.1–6.0,
6.1–7.0, and 7.1–7.8 mmol/l). Differ-
ences in birth weight and birth outcomes
between these five groups were analyzed
by ANOVA and 2 tests for trend. Regres-
sion analyses were also performed using
the continuous variables glucose and
glucose2 to test for nonlinearity.
For the prospective Cambridge Baby
Growth Study, correlations between con-
tinuous variables were tested by linear
regression, adjusted for potential confound-
ing factors (maternal age, height, smoking
in pregnancy, parity, offspring sex, and ges-
tational age). Results of these analyses are
displayed as standardized regression coeffi-
cients (). Insulin levels were positively
skewed, and logarithms were calculated to
achieve normal distributions.
RESULTS
Maternal glucose levels and birth
outcomes
In the retrospective Cambridge Wellbe-
ing study, associations were identified be-
tween various birth outcomes and
maternal glucose levels within the normal
nondiabetic range (glucose level 7.8
mmol/l 60 min after a 50-g glucose load)
(Table 1). Offspring birth weights in-
creased by (mean  SEM) 46  8 g for
each 1 mmol/l rise in maternal 60-min
stimulated glucose level (P 0.0001, n
3,158), and a continuous trend was ap-
parent across the range of normal glucose
levels (Table 1). Each 1 mmol/l increase in
maternal postchallenge glucose levels was
also associated with a rise in the absolute
risk of assisted vaginal deliveries (2.1 
0.8%, P  0.006), emergency cesarean
delivery (3.4  0.8%, P  0.0001), and
elective cesarean delivery (3.1  0.7%,
P 0.0001) (Table 1). No significant de-
viation from linearity was observed for
any outcome (data not shown). T
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Maternal BMI and glucose levels
related to offspring birth size
Maternal characteristics of the prospec-
tive Cambridge Baby Growth Study are
displayed in Table 2. Among women with
normal glycemia (fasting glucose 6.1
mmol/l and 120-min post–75-g OGTT glu-
cose level8.6 mmol/l and reportedly non-
diabetic), distinct effects of maternal
glucose levels and prepregnancy BMI were
seen on infant birth size (Fig. 1). Mother’s
fasting glucose level was more strongly re-
lated to offspring skinfolds ( 0.207, P
0.0001) and weight at birth (  0.180,
P  0.0001) than to birth length ( 
0.097, P  0.02). Conversely, mother’s
prepregnancy BMI was independently re-
lated to offspring birth length (  0.104,
P  0.009) and birth weight (  0.090,
P 0.04) but not to skinfolds at birth (
0.048, P 0.2) (Fig. 1).
The risk of fetal macrosomia (birth
weight 90th centile for gestational age
and sex) was independently related to
both the mother’s fasting glucose (odds
ratio 2.61 per 1 mmol/l [95% CI 1.15–
5.93]) and prepregnancy BMI (1.10 per
1 kg/m2 [1.04–1.18]).
Maternal insulin and glucose
metabolism and offspring adiposity
Offspring skinfolds at birth were more
strongly related to fasting glucose ( 
0.222, P  0.0001) than to 30-min glu-
cose (  0.086), 60-min glucose ( 
0.094), 90-min glucose (  0.074), or
120-min glucose (  0.114, all P 
0.05). Beyond the effect of fasting glu-
cose, stimulated glucose levels did not
further contribute to the variance in off-
spring skinfolds at birth (data not shown).
However, independent of the moth-
er’s glucose levels, the mother’s insulin
sensitivity (  0.129, P  0.01) and
insulin secretion (disposition index,  
0.137, P  0.02) were both inversely
related to offspring skinfolds at birth
(Table 3).
Correlations with adiposity during
infancy
In the prospective Cambridge Baby
Growth Study, prepregnancy BMI corre-
lated positively with offspring adiposity at
ages 12 and 24 months (both P  0.05).
However, the correlation between the
mother’s glycemia and offspring adipos-
ity, which had been apparent at birth, dis-
appeared from age 3 months onward (Fig.
2). Accordingly, higher maternal fasting
glucose levels were associated with a de-
cline in offspring adiposity between birth
to age 12 months (  0.218, P 
0.0001).
CONCLUSIONS— In two contem-
porary U.K. cohorts, we observed that in-
creasing maternal glucose levels within
the normal nondiabetic range were con-
sistently related to larger offspring birth
size and increased risk of interventional
deliveries. Maternal glucose levels specif-
ically enhanced offspring adiposity at
birth, and additional influences of mater-
nal insulin sensitivity and insulin secre-
tion were apparent. Postnatally, the effect
of maternal glycemia on offspring adipos-
ity rapidly disappeared during infancy,
and over the same period a positive effect
of maternal BMI became apparent.
Although gestational diabetes melli-
tus has long been associated with fetal
macrosomia (9), our data support a grow-
ing number of studies that report a con-
tinuous effect of maternal glucose levels,
Figure 1— Distinct influences of the mother’s prepregnancy BMI and gestational fasting glucose
level on offspring size at birth (length, weight, and skinfolds). Standardized correlation coeffi-
cients (  95% CI) from multivariable models that included both BMI and fasting glucose as
determinants are shown. *P 0.05, also adjusted formaternal age, height, smoking in pregnancy,
parity, offspring sex, and gestational age.
Table 2—Characteristics of mothers in the prospective Cambridge Baby Growth Study with
normal glycemia (fasting glucose <6.1 mmol/l and 120 min post–75-g OGTT glucose level
<8.6 mmol/l) and reportedly nondiabetic
Mean Median SD Minimum Maximum
Age (years) 33.3 33.3 4.1 18.1 47.5
Prepregnancy weight (kg) 66.3 63.5 13.1 40.0 143.2
Prepregnancy BMI (kg/m2) 24.1 23.0 4.4 16.6 48.0
Height (cm) 165.9 165.1 7.1 146.0 190.0
Venous glucose
0 min (mmol/l) 4.3 4.3 0.4 2.7 6.0
60 min (mmol/l) 6.6 6.5 1.5 3.0 13.1
Capillary glucose 120 min
(mmol/l) 6.5 6.5 1.0 2.7 8.6
Insulin
0 min (pmol/l) 51.5 43.6 28.1 5.3 347.0
60 min (pmol/l) 406.4 354.7 239.0 38.9 2,315.8
N  668.
Ong and Associates
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even in the absence of maternal diabetes,
on offspring birth weight and pregnancy
outcomes (1,10–13). Most recently, the
international multicenter HAPO Study re-
ported that maternal fasting, 60-min, and
120-min glucose levels all showed similar
linear effects on risks for macrosomia, ce-
sarian delivery, neonatal hypoglycemia,
and insulinemia at birth (1). Such find-
ings indicate that the current criteria used
to diagnose and manage gestational hy-
perglycemia need urgent reconsideration.
Our study shows for the first time that
in addition to maternal glycemia, differ-
ences in maternal insulin sensitivity, in-
sulin secretion, and BMI also have an
impact on offspring size and adiposity.
These findings suggest that maternal en-
ergy substrates other than glucose, such
as free fatty acids or amino acids, may
have an important independent influence
on fetal growth. Although we used the
HOMA model of fasting insulin sensitiv-
ity, smaller studies using the insulinemic-
euglycemic clamp method showed that
maternal insulin sensitivity during preg-
nancy contributes to both offspring body
fat and fat-free mass (14).
The effect of maternal overweight or
obesity on larger offspring size has been
attributed mainly to higher pregnancy
glucose levels. We now show that, inde-
pendent of glycemia, prepregnancy BMI
appears to influence offspring body
length and weight, rather than adiposity.
In contrast, the major effect of maternal
glycemia on fetal growth was on adiposity
(15). Fetal length may be determined at a
very early stage during gestation, whereas
increased adiposity may result largely
from glucose transport to the fetus during
the third trimester. In animal models, ma-
ternal nutrition during the periconcep-
tual period may have important effects on
subsequent fetoplacental growth (16). In
humans, differences in fetal length may
therefore reflect early gestational placen-
tation and periconceptual maternal nutri-
tion. Our findings therefore indicate that
the overweight or obese mother might
somehow enhance early placentation and
early transport of nutrient to the fetus,
possibly by affecting gene methylation
(17).
Offspring of diabetic pregnancies ap-
pear to have increased long-term risks of
obesity (18,19) and impaired glucose tol-
erance (18). It has been suggested that
fetal exposure to glucose increases risks of
overweight and type 2 diabetes in later life
(13). However, such observational stud-
ies cannot completely separate the spe-
cific effects of gestational glucose levels
from inherited genetic susceptibility to
overweight and type 2 diabetes. Our data
show that the effect of maternal glycemia
on offspring adiposity is only transitory
and disappears soon after birth. There-
fore, any deleterious long-term effects of
fetal glucose exposure on type 2 diabetes
risk must be more subtle, possibly affect-
ing fetal -cell capacity or adipocyte dis-
tribution and function rather than overall
adiposity. In contrast, we observed that
the “transgenerational” effects of maternal
BMI on offspring adiposity emerge early
in infancy and could be explained by
transmission of genetic susceptibility to
obesity (20) or by parental influences on
infant nutrition.
In summary, the linear nature of the
associations between maternal glycemia
and adverse birth outcomes leads to un-
certainties in the optimal definition of
gestational hyperglycemia. In addition to
intensive interventions in high-risk indi-
viduals, according to epidemiological
principles, such linear associations indi-
cate that population-based strategies to
reduce glycemia in all pregnant women
would have a greater impact on reducing
adverse pregnancy outcomes in similar
Westernized settings (21). Furthermore,
the aim of such strategies should also be
Figure 2—Distinct postnatal influences of themother’s prepregnancy BMI and gestational fasting
glucose level on offspring skinfold thicknesses during infancy (birth to 24 months). Standardized
correlation coefficients (  95% CI) from multivariable models that included both BMI and
fasting glucose as determinants are shown. *P  0.05.
Table 3—Final multivariable model of determinants of offspring skinfold thicknesses at birth
in the Cambridge Baby Growth Study
Standardized
coefficient () P value
Significant factors
Gestation 0.221 0.001
Female sex 0.111 0.02
Parity 0.127 0.01
Venous glucose 0 min 0.170 0.004
Mother’s insulin sensitivity (HOMA) 0.129 0.01
Mother’s disposition index 0.137 0.02
Nonsignificant factors
Mother’s age 0.081 0.1
Mother’s height 0.077 0.1
Mother’s BMI 0.049 0.3
Smoking 0.004 0.9
Venous glucose 60 min 0.012 0.9
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to reduce maternal prepregnancy BMI
and improve insulin sensitivity as these
factors may influence fetal growth inde-
pendent of maternal glycemia.
Acknowledgments— This project was sup-
ported by a research grant from Wellbeing,
Royal College of Obstetricians and Gynaeco-
logists, U.K. The Cambridge Baby Growth
Study was supported by the European Union
Framework 5, the World Cancer Research
Fund, and the Medical Research Council. B.D.
is supported by the Throne-Holst Foundation,
Uppsala University, Her Royal Highness the
Crown Princess Lovisa’s Foundation for Chil-
dren’s Health Care, the Wera Ekstrom Foun-
dation, and the Swedish Society of Medicine.
We also acknowledge the support of the Cam-
bridge Biomedical Research Center.
We thank all the families in the Cambridge
Baby Growth Study, research nurses, staff at
the Addenbrooke’s Wellcome Trust Clinical
Research Facility, and midwives at the Rosie
Maternity Hospital. We thank Angie Watts for
generous technical assistance.
References
1. Metzger BE, Lowe LP, Dyer AR, Trimble
ER, Chaovarindr U, Coustan DR, Hadden
DR, McCance DR, Hod M, McIntyre HD,
Oats JJ, Persson B, Rogers MS, Sacks DA:
Hyperglycemia and adverse pregnancy
outcomes. N Engl J Med 358:1991–2002,
2008
2. Chellakooty M, Vangsgaard K, Larsen T,
Scheike T, Falck-Larsen J, Legarth J,
Andersson AM, Main KM, Skakkebaek
NE, Juul A: A longitudinal study of intra-
uterine growth and the placental growth
hormone (GH)-insulin-like growth factor
I axis in maternal circulation: association
between placental GH and fetal growth.
J Clin EndocrinolMetab 89:384–391, 2004
3. Redman CW, Sargent IL: Pre-eclampsia,
the placenta and the maternal systemic in-
flammatory response—a review. Placenta
24 (Suppl. A):S21–S27, 2003
4. Sosenko IR, Kitzmiller JL, Loo SW, Blix P,
Rubenstein AH, Gabbay KH: The infant of
the diabetic mother: correlation of in-
creased cord C-peptide levels with mac-
rosomia and hypoglycemia. N Engl J Med
301:859–862, 1979
5. ADA: Gestational diabetes mellitus. Dia-
betes Care 27 (Suppl. 1):S88–S90, 2004
6. Cohen O, Epstein GS, Weisz B, Homko
CJ, Sivan E: Longitudinal assessment of
insulin sensitivity in pregnancy: valida-
tion of the homeostasis model assess-
ment. Clin Endocrinol (Oxf) 64:640–644,
2006
7. Phillips DI, Clark PM, Hales CN, Osmond
C: Understanding oral glucose tolerance:
comparison of glucose or insulin mea-
surements during the oral glucose toler-
ance test with specific measurements of
insulin resistance and insulin secretion.
Diabet Med 11:286–292, 1994
8. Kahn SE: Clinical review 135: the impor-
tance of -cell failure in the development
and progression of type 2 diabetes. J Clin
Endocrinol Metab 86:4047–4058, 2001
9. Jovanovic-Peterson L, Peterson CM, Reed
GF, Metzger BE, Mills JL, Knopp RH,
Aarons JH: Maternal postprandial glucose
levels and infant birth weight: the Diabe-
tes in Early Pregnancy Study: the National
Institute of Child Health and Human De-
velopment—Diabetes in Early Pregnancy
Study. Am J Obstet Gynecol 164:103–111,
1991
10. Parretti E, Mecacci F, Papini M, Cioni R,
Carignani L, Mignosa M, La Torre P,
Mello G: Third-trimester maternal glu-
cose levels from diurnal profiles in non-
diabetic pregnancies: correlation with
sonographic parameters of fetal growth.
Diabetes Care 24:1319–1323, 2001
11. Scholl TO, Chen X, Gaughan C, Smith
WK: Influence of maternal glucose level
on ethnic differences in birth weight and
pregnancy outcome. Am J Epidemiol 156:
498–506, 2002
12. Sermer M, Naylor CD, Gare DJ, Kenshole
AB, Ritchie JW, Farine D, Cohen HR,
McArthur K, Holzapfel S, Biringer A: Im-
pact of increasing carbohydrate intoler-
ance on maternal-fetal outcomes in 3637
women without gestational diabetes: the
Toronto Tri-Hospital Gestational Diabe-
tes Project. Am J Obstet Gynecol 173:146–
156, 1995
13. Franks PW, Looker HC, Kobes S, Touger
L, Tataranni PA, Hanson RL, Knowler
WC: Gestational glucose tolerance and
risk of type 2 diabetes in young Pima In-
dian offspring. Diabetes 55:460–465,
2006
14. Catalano PM, Thomas AJ, Huston LP, Fung
CM: Effect of maternal metabolism on fetal
growth and body composition. Diabetes
Care 21 (Suppl. 2):B85–B90, 1998
15. Manderson J, Mullan B, Patterson C, Had-
den D, Traub A, McCance D: Cardiovas-
cular and metabolic abnormalities in the
offspring of diabetic pregnancy. Diabeto-
logia 45:991–996, 2002
16. MacLaughlin S, Walker S, Roberts C, Kl-
eeman D, McMillen I: Periconceptional
nutrition and the relationship between
maternal body weight changes in the
periconceptional period and fetoplacental
growth in the sheep. J Physiol 565:111–
124, 2005
17. Lillycrop K, Phillips E, Jackson A, Hanson
M, Burdge G: Dietary protein restriction of
pregnant rats induces and folic acid supple-
mentation prevents epigenetic modification
of hepatic gene expression in the offspring. J
Nutr 135:1382–1386, 2005
18. Pettitt DJ, Baird HR, Aleck KA, Bennett
PH, Knowler WC: Excessive obesity in
offspring of Pima Indian women with di-
abetes during pregnancy. N Engl J Med
308:242–245, 1983
19. Pettitt DJ, Aleck KA, Baird HR, Carraher
MJ, Bennett PH, Knowler WC: Congenital
susceptibility to NIDDM: role of intra-
uterine environment. Diabetes 37:622–
628, 1988
20. Lopez-Bermejo A, Petry CJ, Diaz M, Se-
bastiani G, de Zegher F, Dunger DB,
Ibanez L: The association between the
FTO gene and fat mass in humans devel-
ops by the postnatal age of two weeks.
J Clin Endocrinol Metab 93:1501–1505,
2008
21. Rose G: The Strategy of Preventive Medi-
cine. Oxford, Oxford Medical Publica-
tions, 1993
Ong and Associates
DIABETES CARE, VOLUME 31, NUMBER 11, NOVEMBER 2008 2197
